Evidence map›Paper›PMID 26085875›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada

Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature.

Roberto Iacovelli, Daniela Modica, Antonella Palazzo, Patrizia Trenta, Gabriele Piesco, Enrico Cortesi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. The Not-So-Benign Sickle Cell Trait: A Case of Renal Medullary Carcinoma.Journal of community hospital internal medicine perspectives · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Roberto IacovelliSapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.
Daniela ModicaSapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.
Antonella PalazzoSapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.
Patrizia TrentaSapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.
Gabriele PiescoSapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.
Enrico CortesiSapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.
Sapienza University of Rome · ITEuropean Institute of Oncology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe describe clinical features and prognostic factors of renal medullary carcinoma (RMC) by performing a pooled analysis of all reported cases since 1995.

methodsA systematic search was performed to identify all articles describing patients with medullary renal cancer until February 2013. Survivals were estimated using Kaplan-Meier method with 95% confidence intervals and compared across the groups using the log-rank test. The following factors were evaluated using the Cox proportional hazards model: association of extension of disease at diagnosis, response to therapy, and surgical treatment of primary tumour with overall.

resultsA total 47 articles were selected; these described 165 patients with RMC plus 1 from our centre. The median age was 21 years and 98% of cases had the sickle cell trait. The mean size of the primary tumours was 6.0 cm, with an involvement of loco-regional lymph nodes in 71% of cases. The overall survival at diagnosis was 4.0 months in metastatic patients and 17.0 months in non-metastatic patients. Patients who received platinum-paclitaxel-gemcitabine had longer control of the disease when compared to topoisomerase inhibitors or targeted therapies. The multivariate analysis confirmed that the advanced stage at diagnosis increased the risk of death of about threefold.

conclusionRMC is a tumour with poorer prognosis; based on these results, platinum-based chemotherapy is the preferred systemic treatment. Even if radical nephrectomy as an up-front strategy did not report a survival benefit, it may be considered to palliate local symptoms and to perform a correct diagnosis.

Identifiers

PMID26085875
PMCPMC4455635
OpenAlexW2079743297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.